about
Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming Staphylococcus aureus Bovine Mastitis Isolates: A Pilot Study Using Non-Invasive Mouse Mastitis Model.Inflammatory bowel disease: clinical aspects and treatments.Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women.Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis.The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes.The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of β-cells.The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells.The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.Antihypertensive agents do not prevent blood-brain barrier dysfunction and cognitive deficits in dietary-induced obese mice.Advanced bile acid-based multi-compartmental microencapsulated pancreatic β-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells.The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus.Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance.Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.Typing of Staphylococcus aureus isolated from bovine mastitis cases in Australia and India.Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link.Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin.Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic β-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnoloDesigning anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis.New Biotechnological Microencapsulating Methodology Utilizing Individualized Gradient-Screened Jet Laminar Flow Techniques for Pancreatic β-Cell Delivery: Bile Acids Support Cell Energy-Generating Mechanisms.Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment.High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.Oral insulin delivery: existing barriers and current counter-strategies.The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
P50
Q30364039-E04B3E0B-577D-40E6-A2C5-FD832E56E61DQ34431476-B2582439-12A7-4787-AE1C-963A8F5CA96AQ35019769-BF39ABF9-3458-4B4A-A744-928C1A01413BQ35024360-F7C8CF5F-7A63-450C-8358-9C9EB7D1E424Q38712366-6EE6AD31-7BC3-49CD-A36D-7AC9B8F95DD5Q38749074-508B5A3C-3DB2-4297-B39B-AC5BA072A54EQ38769600-EEEA2839-4D85-4ACC-B2AE-EF6A86445696Q38792786-FFCD0D2B-9985-4C97-BF3B-03E7D7FCFA33Q38799022-1EC6DB4F-7E7B-4895-861F-4B9B23E0B1F6Q38811553-FAF12617-7528-47F5-8CB3-AE03AA49EBCDQ38816417-557CE344-FFC5-41F9-A2E2-60D8885741E4Q38834909-AA5AE97D-A0D4-44E6-A36E-CDF2A5F30B6EQ38846334-10A28334-3007-446F-9439-011EF8C2B768Q38940976-93C2D6C7-F9F9-4599-B4A1-8A190B981CCCQ38943790-CF7F1F7F-6F98-4CFB-997C-0E7F33457467Q38976374-8E05D62B-1368-4A76-9CA9-6DFD7F5DF2CAQ39321884-5A1DF531-7221-4B05-BBDD-0E725B262E8AQ39351329-EE3490F5-0831-4D09-8714-B40E69B79EE6Q39739937-EC8BCB7A-2556-483F-AE4C-0139CED3377BQ40509847-E451F09A-0A4B-45EC-8DB0-9B837FCE1F45Q41085273-F6D5C0ED-53AE-442A-80A5-1CEFA8E71F7CQ42770089-0A70C950-90D7-4789-B034-FB7872FC40ACQ42921986-1A6A03FD-BE89-4CED-9AFD-81B82BB86D7BQ42935253-35F78838-8411-4ECE-9DB4-714CC71FF19FQ43808142-FB6FB37C-8101-48F8-B5CC-7022025CA24EQ45915180-E74C81AB-7702-43D4-AFBD-5321CA82E697Q46000543-B7247ACF-AB52-442F-82B4-17EC0F14386AQ46248679-B679CEEA-822C-4146-9104-0D33369C0FC9Q46382050-9B048153-5F94-4996-AF34-ECEFC1A81674Q46534872-D4376C01-766F-4AC3-8D12-0AD9E524C54BQ47106839-305CAC86-D0FA-4962-89A1-CB772A109CF0Q47758976-5C5692C6-52E7-4F44-8548-719486D66808Q47835150-CB76182F-88EF-41C5-8A69-43D6BFD6BC61Q47919403-D5229998-1B8D-4F02-BB2D-8B738AB5A474Q47953446-A3F94578-4D6C-4B7E-886B-7F9F9761F176Q47957547-71454320-A08E-46EC-B885-973E513FEFDFQ48089000-5C0D6766-ADB1-4349-9635-BE2C7DCC442BQ48177243-366D3484-D7E6-4D33-90DD-BBD2C91D62C8Q48203947-766A5E5F-5276-4237-A4DE-DFF2E9C73C40Q48291159-98870BA2-5A56-4B1D-BCF8-17C10F28E617
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hani Al-Salami
@ast
Hani Al-Salami
@en
Hani Al-Salami
@es
Hani Al-Salami
@nl
Hani Al-Salami
@sl
type
label
Hani Al-Salami
@ast
Hani Al-Salami
@en
Hani Al-Salami
@es
Hani Al-Salami
@nl
Hani Al-Salami
@sl
prefLabel
Hani Al-Salami
@ast
Hani Al-Salami
@en
Hani Al-Salami
@es
Hani Al-Salami
@nl
Hani Al-Salami
@sl
P106
P1153
24330693200
P31
P496
0000-0003-0049-6969